There are currently 183 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
NCT06149910
Recruiting
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts clas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: All4Cure, Seattle, Washington
Conditions: Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Recruiting
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/23/2024
Locations: University of Chicago, Chicago, Illinois +7 locations
Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Register for Updates
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Recruiting
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of c... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Register for Updates
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Recruiting
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
Register for Updates
Integrated Actionable Aging Assessment for Cancer Patients Pilot
NCT05871008
Recruiting
Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effor... Read More
Gender:
ALL
Ages:
Between 65 years and 111 years
Trial Updated:
03/13/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: City of Hope, Duarte, California +14 locations
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
NCT06073353
Recruiting
This clinical trial aims to evaluate whether a psychosocial mobile application (THRIVE-M), is efficacious for improving quality of life, psychological distress, and fatigue in patients living with multiple myeloma compared to usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
NCT04663100
Recruiting
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Multiple Chronic Conditions
Register for Updates
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Recruiting
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Global Oncology, Inc., Alhambra, California +12 locations
Conditions: Multiple Myeloma
Register for Updates
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04942067
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Mayo Clinic, Jacksonville, Florida +2 locations
Conditions: Multiple Myeloma, Amyloidosis
Register for Updates
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761
Recruiting
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/29/2023
Locations: Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
Conditions: Multiple Myeloma
Register for Updates